tickrz reports
tickrz rank
C
Biogen Inc (BIIB)
Healthcare | Drugs
318.11  -0.96%
FACTOR RANKINGSFACTOR SCREENER 
tickrz RankC / 267Warren Buffett RankB / 207
Pure Value RankC / 320Dividend RankD / NO DIVIDEND
Moat RankA / 22Financial Strength RankA / 53
Growth RankA / 18Momentum RankC / 334
BIIB vs DRUGS SECTOR & S&P 500
VALUATION
BIIBSECTORS&P 500
P/E RATIO20.6935.719.28
EV/EBITDA RATIO12.5725.111.77
P/S RATIO5.817.12.03
P/B RATIO5.888.73.09
QUALITY
RETURN ON EQUITY28.62%16.98%13.82%
RETURN ON CAPITAL29.69%26.23%10.04%
NET MARGIN36.32%14.46%9.76%
DIVIDEND ANALYSIS
DIVIDEND YIELD
0%
PAYOUT RATIO9.21%
3 YR DIVIDEND GROWTHN/A
FINANCIAL STRENGTH
PIOTROSKI F SCORE
5 OUT OF 9
DEBT-TO-EQUITY56%
INTEREST COVERAGE17.18x
CURRENT RATIO2.1
GROWTH
5 YR EPS GROWTH27.41%
5 YR SPS GROWTH19.33%
5 YR BPS GROWTH16.2%
About tickrz
Key Concepts
Great Investors
Biogen Inc 's strong growth translates to a Growth Rank in the top 25% of all stocks
tickrz rank C / 267
Biogen Inc receives a C ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
value
pure value ranking C / 320Warren Buffett ranking B / 207
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Biogen Inc's valuation score is comprised of a P/E ratio of 20.7x, a P/B ratio of 5.9x, a P/S ratio of 5.8x, and an EV/EBITDA ratio of 12.6x. Biogen Inc ranks 320 out of the S&P 500 constituents on valuation--a relatively weak score.Biogen Inc ranks 207 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a average score, meaning it ranks in the middle of the pack on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Biogen Inc is probably not for you. However, the company's moat is strong so it could be worth investigating in the future should its valuation improve.

quality
moat A / 22financial strength A / 53
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. Biogen Inc appears to have a durable competitive advantage within the Healthcare sector. Biogen Inc has a Piotroski F Score of 5 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 17.18x, a debt/equity ratio of 56% and a Moat Rank of 22 translate to a strong Financial Strength score.


momentum C / 334
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 3.22% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 334. Based on its 12 month stock performance, Biogen Inc will not appeal to momentum investors.

yield D / NO DIVIDEND
value + yield
Biogen Inc currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

growth A / 18
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 27.4% 5 year annualized EPS growth, 19.3% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 16.2% speak to its impressive growth ranking.

Biogen Inc (BIIB)
Healthcare | Drugs
318.11  -0.96%


tickrz rank
C
VALUATION RATIOS
P/E Ratio20.69x
P/B Ratio5.88x
P/S Ratio5.81x
EV/EBITDA Ratio12.57x
DIVIDEND ANALYSIS
DIVIDEND YIELD
0%
PAYOUT RATIO9.21%
3 YR DIVIDEND GROWTHN/A
FINANCIAL STRENGTH
PIOTROSKI F SCORE
5 OUT OF 9
DEBT-TO-EQUITY56%
INTEREST COVERAGE17.18x
CURRENT RATIO2.1
MOAT
ROE28.62%
ROIC29.69%
Net Margin36.32%
GROWTH
5 YR EPS GROWTH27.41%
5 YR SPS GROWTH19.33%
5 YR BPS GROWTH16.2%

TICKRZ RANK
Biogen Inc receives a C ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Biogen Inc's valuation score is comprised of a P/E ratio of 20.7x, a P/B ratio of 5.9x, a P/S ratio of 5.8x, and an EV/EBITDA ratio of 12.6x. Biogen Inc ranks 320 out of the S&P 500 constituents on valuation--a relatively weak score.

WARREN BUFFETT RANKING
Biogen Inc ranks 207 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a average score, meaning it ranks in the middle of the pack on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Biogen Inc is probably not for you. However, the company's moat is strong so it could be worth investigating in the future should its valuation improve.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. Biogen Inc appears to have a durable competitive advantage within the Healthcare sector.

FINANCIAL STRENGTH
Biogen Inc has a Piotroski F Score of 5 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 17.18x, a debt/equity ratio of 56% and a Moat Rank of 22 translate to a strong Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 3.22% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 334. Based on its 12 month stock performance, Biogen Inc will not appeal to momentum investors.

VALUE + YIELD
Biogen Inc currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 27.4% 5 year annualized EPS growth, 19.3% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 16.2% speak to its impressive growth ranking.